News - Peripheral T-cell lymphoma
2010-09-14 06:30:00
PHILADELPHIA, Sept. 14 /PRNewswire/ -- TenX Biopharma, Inc. announced today that data from a Phase II trial of zanolimumab (HuMax-CD4®) in peripheral T-cell Lymphoma (PTCL) were published in the British Journal of Haematology (Sep 2010: 150(5):565-73).
2007-05-16 09:00:36
Gloucester Pharmaceuticals, Inc., an oncology focused biopharmaceutical company, announced today that the U.S.
2007-01-30 09:03:54
Gloucester Pharmaceuticals, Inc., an oncology focused specialty pharmaceutical company, announced today that it has reached an agreement with the U.S.
